Resistance and cross-resistance among protease inhibitors Resistant to: Cross-resistance profile SQV 10/12 patients with L90M + 48 had complete or partial loss of sensitivity to other protease inhibitors. RTV Most or all RTV-resistant isolates are resistant to IDV and NFV…
Four in Favor, Four Against; Long-Awaited Non-Nuke Receives Mixed Reviews at Agency Hearing Clinical benefit elusive In a November 22nd FDA hearing that harkened back to the bad old days of ddC, the Food and Drug Administration's Antiviral Drugs Advisory…
At NIH-Sponsored 'Principles' Panel, A First Peek at Second Phase Decay Data -- and at Lymphoid Architecture FDCs as storage depots In mid-November, an NIH panel convened under the auspices of the Office of AIDS Research (OAR) to discuss scientific…
"It's the Faucet, Stupid." Comparing something called telomere lengths of CD4+ and CD8+ T lymphocytes in HIV-infected and uninfected persons, Amsterdam's Frank Miedema et al. claim "there is no evidence for increased turnover of CD4+ T cells in HIV infection."…
Devastating Funding Proposal Undermines the Global Fight Against AIDS by Coco Jervis A sense of disbelief washed over the global AIDS community last month when President Obama unveiled his fiscal year 2013 budget proposal to cut $563 million from the…
Merck’s Cavalier Attitude Toward the Welfare of HIV/HCV-Coinfected Patients by Tracy Swan In places where access to antiretroviral therapy is widespread, people living with HIV are now dying from a common and curable coinfection: hepatitis C virus (HCV). HIV increases…
by Richard Jefferys In the earliest days after the discovery of HIV in the mid-1980s, uncertainty reigned regarding how the immune system responded to the virus. Initially, it was thought that the time between HIV infection and the development of…
TAG at 20: Early Campaigns; The Odyssey of Therapeutic Vaccines for HIV; What You Don’t Know, You Can Sell; Does Obama’s 2013 Budget Herald the End of PEPFAR?; Childhood TB Advocacy Picks Up Steam
Reforming NIH AIDS Research, Boosting the Budget, and Revitalizing the Basic Science of HIV Infection by Mark Harrington On January 22, 2012, the Treatment Action Group marked its twentieth anniversary. Over the past two decades, we have helped to accelerate…
As representatives of organizations that advocate for an evidence-based and robust response to global AIDS, we respond to your fiscal year 2013 budget request for the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)—the flagship bilateral AIDS program—with shock and dismay.